Increased tumor-associated mast cells facilitate thyroid cancer progression by inhibiting CD8+ T cell function through galectin-9

As an important component of solid tumors, mast cells show specific phenotypes in various tumor microenvironments. However, the precise mechanism of mast cell accumulation and the phenotypic features of thyroid cancer (TC) remain largely unknown. Here, we found that mast cells were obviously recruited to tumor tissue by TC-derived stem cell factor (SCF). With tumor progression, mast cell levels increased gradually. In addition, intratumoral mast cells expressed higher levels of the immunosuppressive molecule galectin-9, which effectively suppresses CD8+ T-cell antitumor immunity in vitro. Blocking galectin-9 on tumor-infiltrating mast cells reversed the immunosuppression of CD8+ T cells. In conclusion, our data elucidated novel protumorigenic and immunosuppressive roles of mast cells in TC. In addition, our results indicated that blocking mast cells may impede tumor progression and ameliorate the prognosis of TC patients.

[1]  G. Marone,et al.  Immune and Inflammatory Cells in Thyroid Cancer Microenvironment , 2019, International journal of molecular sciences.

[2]  G. Sammarco,et al.  Mast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer , 2019, International journal of molecular sciences.

[3]  R. Melillo,et al.  Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies , 2019, F1000Research.

[4]  Y. Zhuang,et al.  Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway , 2019, Journal of Immunotherapy for Cancer.

[5]  G. Sammarco,et al.  Tumor-Associated Macrophages and Mast Cells Positive to Tryptase Are Correlated with Angiogenesis in Surgically-Treated Gastric Cancer Patients , 2018, International journal of molecular sciences.

[6]  Shimin Wang,et al.  Tumor‐infiltrating tryptase+ mast cells predict unfavorable clinical outcome in solid tumors , 2018, International journal of cancer.

[7]  A. Mantovani,et al.  Mast Cell–Dependent CD8+ T-cell Recruitment Mediates Immune Surveillance of Intestinal Tumors in ApcMin/+ Mice , 2018, Cancer Immunology Research.

[8]  F. Granata,et al.  Are Mast Cells MASTers in Cancer? , 2017, Front. Immunol..

[9]  S. Devesa,et al.  Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013 , 2017, JAMA.

[10]  S. Nonogaki,et al.  CD8+ tumour‐infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer , 2015, Clinical endocrinology.

[11]  V. Aidinis,et al.  Mast cells mediate malignant pleural effusion formation. , 2015, The Journal of clinical investigation.

[12]  Florian Klemm,et al.  Microenvironmental regulation of therapeutic response in cancer. , 2015, Trends in cell biology.

[13]  R. Franco,et al.  Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8–Akt–Slug pathway , 2015, Oncogene.

[14]  M. Luster,et al.  Differentiated thyroid cancer—personalized therapies to prevent overtreatment , 2014, Nature Reviews Endocrinology.

[15]  Z. Illés,et al.  Peripheral Blood TIM-3 Positive NK and CD8+ T Cells throughout Pregnancy: TIM-3/Galectin-9 Interaction and Its Possible Role during Pregnancy , 2014, PloS one.

[16]  S. Pileri,et al.  Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. , 2014, Blood.

[17]  Stephen J Galli,et al.  Mast Cells: Potential Positive and Negative Roles in Tumor Biology , 2013, Cancer Immunology Research.

[18]  S. Nonogaki,et al.  Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma , 2012, Clinical endocrinology.

[19]  R. Stan,et al.  Mast cells impair the development of protective anti-tumor immunity , 2012, Cancer Immunology, Immunotherapy.

[20]  Stephen J Galli,et al.  IgE and mast cells in allergic disease , 2012, Nature Medicine.

[21]  R. McIntyre,et al.  Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[23]  M. Santoro,et al.  Mast cells have a protumorigenic role in human thyroid cancer , 2010, Oncogene.

[24]  D. Ingber,et al.  Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  H. Xiong,et al.  SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. , 2008, Blood.

[26]  T. Niki,et al.  Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.

[27]  V. Kuchroo,et al.  The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.

[28]  M. J. Abedin,et al.  Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance , 2002, International journal of cancer.

[29]  T. Carling,et al.  Thyroid cancer. , 2014, Annual review of medicine.